Short answer
Baxter International (BAX) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $3.0B (up 5.3% year over year) with net income of $126M.
Q2 2026 key financials · XBRL
- Revenue
- $3.0B
- +5.3% YoY · +9.6% QoQ
- Net income
- $126M
- +38.5% YoY · +940.0% QoQ
- Operating margin
- 7.3%
- Gross margin
- 34.9%
- EPS (diluted)
- $0.24
- +41.2% YoY · +900.0% QoQ
Source: XBRL data from the Baxter International (BAX) Q2 2026 10-Q on SEC EDGAR. USD.
Baxter International Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $2.960B, up 5% YoY from $2.810B
- Advanced Surgery best performer, sales $331M, up 12% YoY
- Front Line Care weakest, sales $299M, up 2% YoY
- Tariff refunds of approximately $75M recorded against cost of goods sold
- Headwinds: Novum LVP hold, supply constraints, tariffs, inflation, geopolitical uncertainty, and potentially lower hospital capital spending
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report
- Regulatory compliance risk: officer trading arrangements subject to Rule 10b5-1 requirements
- Governance risk: amended certificate, bylaws, and executive severance plan effective May 8, 2026
- Financial flexibility: $1.30 billion remaining under the share repurchase authorization as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Baxter International quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.